Assessment and Tracking of Long-term Alefacept Safety

• Status: Terminated
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Subjects exposed to alefacept are to be enrolled. Subjects will be contacted every 6 months to gather general health information.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Alefacept

Criteria

Inclusion Criteria:

• Psoriasis patients who are prescribed alefacept consistent with product labeling are eligible for enrollment.